Overall, the reduction of hepatic Ucp2 and Nos2 expression in DIO mice treated with PGG indicated a preventive effect on obesity but also on non-alcoholic steatohepatitis. The gene discussed is UCP2; the disease is metabolic dysfunction-associated steatohepatitis.